Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (251-260 of 269) with videos related to

Pageof 27
Sort By:
Gut|November 1, 2014
Reproducibility of histological assessments of disease activity in UCMahmoud H Mosli, Brian G Feagan, Guangyong Zou, et al.
Lancet (London, England)|February 26, 2008
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialGeert D'Haens, Filip Baert, Gert van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 20, 2025
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's DiseaseSudheer Kumar Vuyyuru, Jurij Hanzel, Mantaj S Brar, et al.
Gastroenterology|November 13, 2019
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of ProteinsGeert D'Haens, Orlaith Kelly, Robert Battat, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Nature Reviews. Gastroenterology & Hepatology|June 3, 2024
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practiceDominik Bettenworth, Mark E Baker, Joel G Fletcher, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Clinical and Translational Gastroenterology|November 3, 2017
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter StudyLiset Westera, Tanja van Viegen, Jenny Jeyarajah, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Pageof 27

Showing results (251-260 of 269) with videos related to

Sort By:
Pageof 27
Gut|November 1, 2014
Reproducibility of histological assessments of disease activity in UCMahmoud H Mosli, Brian G Feagan, Guangyong Zou, et al.
Lancet (London, England)|February 26, 2008
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trialGeert D'Haens, Filip Baert, Gert van Assche, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 20, 2025
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's DiseaseSudheer Kumar Vuyyuru, Jurij Hanzel, Mantaj S Brar, et al.
Gastroenterology|November 13, 2019
Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of ProteinsGeert D'Haens, Orlaith Kelly, Robert Battat, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Nature Reviews. Gastroenterology & Hepatology|June 3, 2024
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practiceDominik Bettenworth, Mark E Baker, Joel G Fletcher, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Clinical and Translational Gastroenterology|November 3, 2017
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter StudyLiset Westera, Tanja van Viegen, Jenny Jeyarajah, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Gastroenterology|September 22, 2014
Development of the Lémann index to assess digestive tract damage in patients with Crohn's diseaseBenjamin Pariente, Jean-Yves Mary, Silvio Danese, et al.
Pageof 27